© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 19, 1473-1478,
October 3, 2001
© 2001 Oxford University Press
REPORT |
In Vitro Evidence for Homologous Recombinational Repair in Resistance to Melphalan
Affiliations of authors: Z.-M. Wang, Z.-Y. Xu, G. Christodoulopoulos, V. Bello, G. Mohr, R. Aloyz, L. C. Panasci, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, PQ, Canada; Z.-P. Chen, Department of Neurosurgery/Neuro-Oncology, Cancer Center, Sun Yat-sen University of Medical Sciences, People's Republic of China, Guangzhou.
Correspondence to: Lawrence C. Panasci, M.D., Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, 3755 Côte Ste Catherine, Montreal, PQ, H3T 1E2 Canada (e-mail: lpanasci{at}hotmail.com).
Background: The generation of DNA interstrand cross-links is thought to be important in the cytotoxicity of nitrogen mustard alkylating agents, such as melphalan, which have antitumor activity. Cell lines with mutations in recombinational repair pathways are hypersensitive to nitrogen mustards. Thus, resistance to melphalan may require accelerated DNA repair by either recombinational repair mechanisms involving Rad51-related proteins (including x-ray repair cross-complementing proteins Xrcc2, Xrcc3, and Rad52) or by nonhomologous endjoining involving DNA-dependent protein kinase (DNA-PK) and Ku proteins. We investigated the role of DNA repair in melphalan resistance in epithelial tumor cell lines. Methods: Melphalan cytotoxicity was determined in 14 epithelial tumor cell lines by use of the sulforhodamine assay. Homologous recombinational repair involving Rad51-related proteins was investigated by determining the levels of Rad51, Rad52, and Xrcc3 proteins and the density of nuclear melphalan-induced Rad51 foci, which represent sites of homologous recombinational repair. Nonhomologous endjoining was investigated by determining the levels of Ku70 and Ku86 proteins and DNA-PK activity. Linear regression analysis was used to analyze correlations between the various protein levels, DNA-PK activity, or Rad51 foci formation and melphalan cytotoxicity. All statistical tests were two-sided. Results: Melphalan resistance was correlated with Xrcc3 levels (r = .587; P = .027) and the density of melphalan-induced Rad51 foci (r = .848; P = .008). We found no correlation between melphalan resistance and Rad51, Rad52, or Ku protein levels or DNA-PK activity. Conclusion: Correlations of melphalan resistance in epithelial tumor cell lines with Xrcc3 protein levels and melphalan-induced Rad51 foci density suggest that homologous recombinational repair is involved in resistance to this nitrogen mustard.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Zhou, J. Teruya-Feldstein, P. Lu, M. Fleisher, A. Olshen, and R. L Comenzo Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan Blood, January 15, 2008; 111(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials Blood, May 1, 2007; 109(9): 3936 - 3944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-Y. Xu, M. Loignon, F.-Y. Han, L. Panasci, and R. Aloyz Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced Apoptosis J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 495 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Ritchey, W.-Y. Huang, A. P. Chokkalingam, Y.-T. Gao, J. Deng, P. Levine, F. Z. Stanczyk, and A. W. Hsing Genetic Variants of DNA Repair Genes and Prostate Cancer: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1703 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. K. Mukhopadhyay, A. M. Senderowicz, and G. Ferbeyre RNA Silencing of Checkpoint Regulators Sensitizes p53-Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells Cancer Res., April 1, 2005; 65(7): 2872 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Libura, D. J. Slater, C. A. Felix, and C. Richardson Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion Blood, March 1, 2005; 105(5): 2124 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Friedmann, M. Caplin, J. A. Hartley, and D. Hochhauser Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) Clin. Cancer Res., October 1, 2004; 10(19): 6476 - 6486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Aloyz, Z.-Y. Xu, V. Bello, J. Bergeron, F.-Y. Han, Y. Yan, A. Malapetsa, M. A. Alaoui-Jamali, A. M. V. Duncan, and L. Panasci Regulation of Cisplatin Resistance and Homologous Recombinational Repair by the TFIIH Subunit XPD Cancer Res., October 1, 2002; 62(19): 5457 - 5462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Spanswick, C. Craddock, M. Sekhar, P. Mahendra, P. Shankaranarayana, R. G. Hughes, D. Hochhauser, and J. A. Hartley Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma Blood, June 17, 2002; 100(1): 224 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fojo Cancer, DNA Repair Mechanisms, and Resistance to Chemotherapy J Natl Cancer Inst, October 3, 2001; 93(19): 1434 - 1436. [Full Text] [PDF]
|
|